The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Colin Baigent; Martin J Landray; Christina Reith; Jonathan Emberson; David C Wheeler; Charles Tomson; Christoph Wanner; Vera Krane; Alan Cass; Jonathan Craig; Bruce Neal; Lixin Jiang; Lai Seong Hooi; Adeera Levin; Lawrence Agodoa; Mike Gaziano; Bertram Kasiske; Robert Walker; Ziad A Massy; Bo Feldt-Rasmussen; Udom Krairittichai; Vuddidhej Ophascharoensuk; Bengt Fellström; Hallvard Holdaas; Vladimir Tesar; Andrzej Wiecek; Diederick Grobbee; Dick de Zeeuw; Carola Grönhagen-Riska; Tanaji Dasgupta; David Lewis; William Herrington; Marion Mafham; William Majoni; Karl Wallendszus; Richard Grimm; Terje Pedersen; Jonathan Tobert; Jane Armitage; Alex Baxter; Christopher Bray; Yiping Chen; Zhengming Chen; Michael Hill; Carol Knott; Sarah Parish; David Simpson; Peter Sleight; Alan Young; Rory Collins; SHARP Investigators

doi:10.1016/S0140-6736(11)60739-3

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano, Bertram Kasiske, Robert Walker, Ziad A Massy, Bo Feldt-RasmussenUdom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick de Zeeuw, Carola Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins, SHARP Investigators

2189 Citationer (Scopus)

Abstract

Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.

Originalsprog	Engelsk
Tidsskrift	Lancet
Vol/bind	377
Udgave nummer	9784
Sider (fra-til)	2181-92
Antal sider	12
ISSN	0140-6736
DOI	https://doi.org/10.1016/S0140-6736(11)60739-3
Status	Udgivet - 2011

Adgang til dokumentet

10.1016/S0140-6736(11)60739-3

Citationsformater

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., Neal, B., Jiang, L., Hooi, L. S., Levin, A., Agodoa, L., Gaziano, M., Kasiske, B., Walker, R., Massy, Z. A., ... SHARP Investigators (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet, 377(9784), 2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. / Baigent, Colin; Landray, Martin J; Reith, Christina et al.
I: Lancet, Bind 377, Nr. 9784, 2011, s. 2181-92.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Baigent, C, Landray, MJ, Reith, C, Emberson, J, Wheeler, DC, Tomson, C, Wanner, C, Krane, V, Cass, A, Craig, J, Neal, B, Jiang, L, Hooi, LS, Levin, A, Agodoa, L, Gaziano, M, Kasiske, B, Walker, R, Massy, ZA, Feldt-Rasmussen, B, Krairittichai, U, Ophascharoensuk, V, Fellström, B, Holdaas, H, Tesar, V, Wiecek, A, Grobbee, D, de Zeeuw, D, Grönhagen-Riska, C, Dasgupta, T, Lewis, D, Herrington, W, Mafham, M, Majoni, W, Wallendszus, K, Grimm, R, Pedersen, T, Tobert, J, Armitage, J, Baxter, A, Bray, C, Chen, Y, Chen, Z, Hill, M, Knott, C, Parish, S, Simpson, D, Sleight, P, Young, A, Collins, R & SHARP Investigators 2011, 'The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial', Lancet, bind 377, nr. 9784, s. 2181-92. https://doi.org/10.1016/S0140-6736(11)60739-3

@article{2aee997f08144e4e830b5864c464a05e,

title = "The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial",

abstract = "Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.",

keywords = "Adult, Aged, Azetidines, Cardiovascular Diseases, Cholesterol, LDL, Confidence Intervals, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypolipidemic Agents, Kidney Function Tests, Male, Middle Aged, Reference Values, Renal Dialysis, Renal Insufficiency, Chronic, Risk Assessment, Severity of Illness Index, Simvastatin, Survival Analysis, Time Factors, Treatment Outcome",

author = "Colin Baigent and Landray, {Martin J} and Christina Reith and Jonathan Emberson and Wheeler, {David C} and Charles Tomson and Christoph Wanner and Vera Krane and Alan Cass and Jonathan Craig and Bruce Neal and Lixin Jiang and Hooi, {Lai Seong} and Adeera Levin and Lawrence Agodoa and Mike Gaziano and Bertram Kasiske and Robert Walker and Massy, {Ziad A} and Bo Feldt-Rasmussen and Udom Krairittichai and Vuddidhej Ophascharoensuk and Bengt Fellstr{\"o}m and Hallvard Holdaas and Vladimir Tesar and Andrzej Wiecek and Diederick Grobbee and {de Zeeuw}, Dick and Carola Gr{\"o}nhagen-Riska and Tanaji Dasgupta and David Lewis and William Herrington and Marion Mafham and William Majoni and Karl Wallendszus and Richard Grimm and Terje Pedersen and Jonathan Tobert and Jane Armitage and Alex Baxter and Christopher Bray and Yiping Chen and Zhengming Chen and Michael Hill and Carol Knott and Sarah Parish and David Simpson and Peter Sleight and Alan Young and Rory Collins and {SHARP Investigators}",

year = "2011",

doi = "10.1016/S0140-6736(11)60739-3",

language = "English",

volume = "377",

pages = "2181--92",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier BV",

number = "9784",

}

TY - JOUR

T1 - The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

AU - Baigent, Colin

AU - Landray, Martin J

AU - Reith, Christina

AU - Emberson, Jonathan

AU - Wheeler, David C

AU - Tomson, Charles

AU - Wanner, Christoph

AU - Krane, Vera

AU - Cass, Alan

AU - Craig, Jonathan

AU - Neal, Bruce

AU - Jiang, Lixin

AU - Hooi, Lai Seong

AU - Levin, Adeera

AU - Agodoa, Lawrence

AU - Gaziano, Mike

AU - Kasiske, Bertram

AU - Walker, Robert

AU - Massy, Ziad A

AU - Feldt-Rasmussen, Bo

AU - Krairittichai, Udom

AU - Ophascharoensuk, Vuddidhej

AU - Fellström, Bengt

AU - Holdaas, Hallvard

AU - Tesar, Vladimir

AU - Wiecek, Andrzej

AU - Grobbee, Diederick

AU - de Zeeuw, Dick

AU - Grönhagen-Riska, Carola

AU - Dasgupta, Tanaji

AU - Lewis, David

AU - Herrington, William

AU - Mafham, Marion

AU - Majoni, William

AU - Wallendszus, Karl

AU - Grimm, Richard

AU - Pedersen, Terje

AU - Tobert, Jonathan

AU - Armitage, Jane

AU - Baxter, Alex

AU - Bray, Christopher

AU - Chen, Yiping

AU - Chen, Zhengming

AU - Hill, Michael

AU - Knott, Carol

AU - Parish, Sarah

AU - Simpson, David

AU - Sleight, Peter

AU - Young, Alan

AU - Collins, Rory

AU - SHARP Investigators

PY - 2011

Y1 - 2011

N2 - Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.

AB - Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.

KW - Adult

KW - Aged

KW - Azetidines

KW - Cardiovascular Diseases

KW - Cholesterol, LDL

KW - Confidence Intervals

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Drug Administration Schedule

KW - Drug Therapy, Combination

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hypolipidemic Agents

KW - Kidney Function Tests

KW - Male

KW - Middle Aged

KW - Reference Values

KW - Renal Dialysis

KW - Renal Insufficiency, Chronic

KW - Risk Assessment

KW - Severity of Illness Index

KW - Simvastatin

KW - Survival Analysis

KW - Time Factors

KW - Treatment Outcome

U2 - 10.1016/S0140-6736(11)60739-3

DO - 10.1016/S0140-6736(11)60739-3

M3 - Journal article

C2 - 21663949

SN - 0140-6736

VL - 377

SP - 2181

EP - 2192

JO - Lancet

JF - Lancet

IS - 9784

ER -

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater